Partner with Us!
We believe in the power of partnership and collaboration to drive transformative advancements. As passionate advocates of innovation, we understand that together, we can achieve far more than we can alone. If you are interested in partnering, contact email@example.com.
On August 2, 2022, Xenetic entered into a research and development collaboration with Volition to develop NETs-targeted adoptive cell therapies for the treatment of cancer. The collaboration is an early exploratory program to evaluate the potential combination of Volition’s Nu.Q® technology Test and our DNase-Armored CAR T platform to develop proprietary adoptive cell therapies potentially targeting multiple types of solid cancers.
Takeda Pharmaceutical Co. Ltd.
In October 2017, the Xenetic granted to Takeda the right to grant a non-exclusive sublicense to certain patents related to our PolyXen technology that were previously exclusively licensed to Takeda in connection with products related to the treatment of blood and bleeding disorders. We receive royalty payments from this agreement.
CLS Therapeutics Ltd.
On April 26, 2022, Xenetic entered into an Exclusive Sublicense Agreement with CLS pursuant to which the Company received an exclusive license, under certain patent rights and know-how owned or controlled by CLS, to develop and commercialize pharmaceutical products and methods incorporating DNase enzyme for use in treatment of cancer.
Catalent Pharma Solutions LLC
On June 30, 2022, Xenetic entered into an agreement with Catalent for certain services to our perform cGMP manufacturing of recombinant protein, Human DNase I.
On March 17, 2023, Xenetic and Scripps Research entered into a Research Funding and Option Agreement advancing the pre-clinical development of our DNase oncology platform technology.